2024-01-19

OMDA (OMDA)

OMDA Way to Digitise the Healthcare Sector

OMDA AS ("OMDA" or "the Company") provides scalable software solutions to the healthcare sector, such as emergency response systems, primarily through tenured contracts, ensuring recurring revenue for 10+ years. With political headwinds and a strong cash position, the Company is set to grow organically and through acquisitions. However, reduced reliance on acquired growth facilitates the Company to focus on integrating previous acquisitions, thus enabling greater efficiency, lower operating costs, and higher EBITDA margins through scalable solutions. OMDA is estimated to reach an EBITDA of NOK 150.2m in 2025 and based on an applied EV/EBITDA target multiple of 10.4x, a potential fair value of NOK 49.1 per share is derived in a Base scenario.

Favourable Acquisitions Enables Increased Revenue


Tenders for new suppliers from public-owned hospitals can sometimes take up to ten years; therefore, acquisitions has been the primary strategy for OMDA to gain new customers and revenue streams. However, the Swedish and Norwegian governments have set aside SEK 660m and NOK 1.25bn, respectively, to digitise healthcare, leading to tenders for new suppliers are estimated to be more frequent going forward. Reduced reliance on acquired growth allows OMDA to focus on growing organically and creating synergies, leading to lower CapEx, which enables higher cash flows. Therefore, Analyst Group estimates that the revenue will grow with a CAGR of 18.1% until 2025, reaching NOK 608.6m.

Positioned to Capitalize on Political Initiatives

Nordic's most prominent public-owned hospitals have used OMDA's software solutions over the past 25 years, and as tenders increase, the Company is well-positioned to capitalize on the demand. OMDA's Coordcom platform, already serving 11% of the European population, aligns with the EU's directive towards NG112, fueling further possible revenue growth. With the healthcare sector's sensitivity to change, contracts of +15 years, and a churn below 2% annually, the stickiness of the solution enables up-selling and price increases. Analyst Group estimates ARR to grow with a CAGR of 21%, primarily through the underlying demand to digitise the European healthcare sector, continued up-selling, and price increases.

Further Integration Provides Compelling Margin Growth

In 2021, OMDA acquired two companies in the emergency segment, initially with EBITDA margins of -4% and 12%. The integration is now completed whereas EBITDA margins have increased to 18.5% YTD. As the 2022 acquired companies' integration period closes in, the EBITDA margins are estimated to increase further as integration-related salary expenses are reduced. With a strong position, serving nearly all hospitals in the Nordics, OMDA can scale the software without higher sales personnel expenses, enabling lower operating costs as a percentage of sales. Analyst Group estimates EBITDA to expand from 12.9% YTD to 24.7% in 2025 through proven integration effects and a scalable SaaS business model.



Owners (Source: The Company, 2023-12-29)				
Equilibrium AS				19.5%
The Northern Trust Comp, London Br				12.8%
The Bank of New York Mellon SA/NV			8.2%	
Pershing LLC				5.0%
DEFA Endeavour AS				4.7%
Estimates (MNOK)	2022A	2023E	2024E	2025E
Revenue	369.7	414.0	498.8	608.6
COGS	33.4	32.9	39.6	45.3
Gross Profit	336.3	377.9	455.3	558.4
Gross Profit Gross Margin	336.3 91.0%	377.9 92.0%	455.3 92.0%	558.4 92.5%
Gross Margin	91.0%	92.0%	92.0%	92.5%
Gross Margin Operating Costs	91.0% 320.7	92.0% 324.9	92.0% 364.3	92.5% 408.2
Gross Margin Operating Costs EBITDA	91.0% 320.7 15.6	92.0% 324.9 52.9	92.0% 364.3 90.9	92.5% 408.2 150.2
Gross Margin Operating Costs EBITDA EBITDA Margin	91.0% 320.7 15.6 4.2%	92.0% 324.9 52.9 12.8%	92.0% 364.3 90.9 18.2%	92.5% 408.2 150.2 24.7%
Gross Margin Operating Costs EBITDA EBITDA Margin P/S	91.0% 320.7 15.6 4.2% 2.0x	92.0% 324.9 52.9 12.8% 1.9x	92.0% 364.3 90.9 18.2% 1.6x	92.5% 408.2 150.2 24.7% 1.3x

Disclaimer

These analyses, documents and any other information originating from AG Equity Research AB (Henceforth "AG) are created for information purposes only, for general dissipation and are not intended to be advisory. The information in the analysis is based on sources, data and persons which AG believes to be reliable. AG can never guarantee the accuracy of the information. The forward-looking information found in this analysis are based on assumptions about the future, and are therefore uncertain by nature and using information found in the analysis should therefore be done with care. Furthermore, AG can never guarantee that the projections and forward-looking statements will be fulfilled to any extent. This means that any investment decisions based on information from AG, any employee or person related to AG are to be regarded to be made independently by the investor. These analyses, documents and any other information derived from AG is intended to be one of several tools involved in investment decisions regarding all forms of investments regardless of the type of investment involved. Investors are urged to supplement with additional relevant data and information, as well as consulting a financial adviser prior to any investment decision. AG disclaims all liability for any loss or damage of any kind that may be based on the use of analyzes, documents and any other information derived from AG.

Conflicts of Interest and impartiality

To ensure AG's independence, AG has established compliance rules for analysts. In addition, all analysts have signed an agreement in which they are required to report any and all conflicts of interest. These terms have been designed to ensure that *COMMISSION DELEGATED REGULATION (EU) 2016/958 of 9 March 2016, supplementing Regulation (EU)* No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest. Compliance policy: https://analystgroup.se/interna-regler-ansvarsbegransning/ (Swedish)

Other

The Principal, **OMDA AS** (furthermore" the Company") has had no opportunity to influence the parts where Analyst Group has had opinions about the Company's future valuation or anything that could constitute an objective assessment.

The analyst does not own shares in the Company.

This analysis is copyright protected by law © AG Equity Research AB (2014-2024). Sharing, dissemination or equivalent action to a third party is permitted provided that the analysis is shared unchanged.